First vaccine for Bundibugyo Ebola hits human trials in Oxford study

Oxford's Ebola vaccine candidate has entered Phase 1 clinical trials for safety evaluation. The ChAdOx1 BDBV vaccine uses a platform similar to the Covid-19 vaccine. Serum Institute of India manufactured approximately 620,000 doses for potential future use. This initiative builds on a strategic partnership with CEPI and the University of Oxford. Late-stage trials will follow if Phase 1 results prove successful.